Thursday, March 14, 2013

Indian Supreme Court, Clinical trials, and Pharma growth

Reading this on a mobile device? Try our optimized mobile version here:http://r.smartbrief.com/resp/enjcCmnpecCigKaRCidyfTDXBJfyrv
March 14, 2013
Sign upForwardArchiveAdvertise
  • Indian court: No need for vegetarian/non-vegetarian labels
    The Indian Supreme Count rejected a lower-court ruling requiring "V" and "NV" labels identifying drugs and cosmetics as either vegetarian or non-vegetarian in origin. In opposing the regulation, the government noted the variability in individual food habits, including broad differences even among vegetarians concerning which foods are acceptable and which are not. The Economic Times (India)(3/12) LinkedInFacebookTwitterEmail this Story
  • Deaths in Indian clinical trials result in few payments
    While 2,868 deaths were reported during clinical trials from 2005 to 2012, the Indian government found only 89 to be directly attributable to the trials. To date, compensation has been paid in only 45 cases. The government has established four committees to monitor the fast-growing growing clinical-trial industry in India, mandating strict requirements for reporting adverse events, including deaths, according to the Ministry of Health and Family Welfare. Business Standard (India)(3/13) LinkedInFacebookTwitterEmail this Story
  • To grow, Indian pharma must embrace innovation, technology
    Indian drug companies must focus on new technologies, including development of "super-generics," in order to grow and flourish, said Andrew Barrett, director of medical technology in India at Cambridge Consultants. "[T]he required investments can be recouped because medical products have long lifecycles," he added. Other experts at a Mumbai conference noted that the biggest growth opportunities will come from innovations to differentiate products, because the number of expiring drug patents has peaked, and other countries are offering greater competition for low-cost generics. PharmaTimes (U.K.)(3/13) LinkedInFacebookTwitterEmail this Story
 
Subscriber Tools
Update account information |Change e-mail address |Unsubscribe |Print friendly format |Web version |Search past news |Archive |Privacy policy

Advertise
Account Director, Life Sciences: Meryl Harold (202) 407-7828
Read more atSmartBrief.com
Recent DIA Global SmartBrief Issues: Lead Editor: Lisa Gough

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2013 SmartBrief, Inc.® Legal Information
 

No comments:

Post a Comment